Aspire Biopharma, Inc. (NASDAQ:PWUP) | WebDisclosure

Basculer en Français

9479	Companies
185504	Keywords
117879	Articles
99354	Press releases

Headlines Articles Press releases Aspire Biopharma, Inc.

Home
Companies
Aspire Biopharma, Inc.

PRESS RELEASE

published on 06/10/2025 at 14:30, 5 months 25 days ago

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
Michael Howe to become CEO of Aspire Biopharma Holdings, Inc. on June 10, 2025. His extensive career in leading brands and early-stage companies makes him a strategic fit for the role

Healthcare Board Member CEO Michael Howe Aspire Biopharma Holdings, Inc.
BRIEF

published on 05/28/2025 at 14:35, 6 months 8 days ago

Aspire Biopharma dévoile BUZZ BOMB™ : une nouvelle ère dans les compléments pré-entraînement

Technologie Sublinguale Marché Du Fitness Supplément Pré-entraînement BUZZ BOMB™ Livraison De Caféine
BRIEF

published on 05/28/2025 at 14:35, 6 months 8 days ago

Aspire Biopharma Unveils BUZZ BOMB™: A New Era in Pre-Workout Supplements

Sublingual Technology Fitness Market Pre-workout Supplement BUZZ BOMB™ Caffeine Delivery
PRESS RELEASE

published on 05/28/2025 at 14:30, 6 months 8 days ago

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
Aspire Biopharma introduces BUZZ BOMB™, a sublingual pre-workout supplement delivering rapid caffeine to support athletes' performance. Six flavors available in convenient single servings. Global pre-workout supplements market on the rise

Aspire Biopharma Pre-workout Supplement Sublingual BUZZ BOMB™ Caffeine
BRIEF

published on 05/20/2025 at 14:35, 6 months 16 days ago

Aspire Biopharma lance un essai de phase 1 sur une formulation d'aspirine à haute dose

Développement Clinique Examen De La FDA Essai De Phase 1 Aspirine À Haute Dose Absorption Sublinguale
BRIEF

published on 05/20/2025 at 14:35, 6 months 16 days ago

Aspire Biopharma Begins Phase 1 Trial of High-Dose Aspirin Formulation

Clinical Development Phase 1 Trial FDA Review High-dose Aspirin Sublingual Absorption
PRESS RELEASE

published on 05/20/2025 at 14:30, 6 months 16 days ago

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma initiates Phase 1 trial for high-dose aspirin formulation in the United States, targeting accelerated approval with positive data anticipated in 3Q 2025

Accelerated Approval Phase 1 Trial FDA Feedback Aspire Biopharma High-dose Aspirin Formulation
BRIEF

published on 05/08/2025 at 14:05, 6 months 28 days ago

Aspire Biopharma to Participate in Sidoti Virtual Investor Conference

Investor Presentation Drug Delivery Technology Sidoti Conference Aspire Biopharma Virtual Meetings
BRIEF

published on 05/08/2025 at 14:05, 6 months 28 days ago

Aspire Biopharma participera à la conférence virtuelle des investisseurs de Sidoti

Presentation Aux Investisseurs Technologie D'administration De Médicaments Conférence De Sidoti Aspire Biopharma Réunions Virtuelles
PRESS RELEASE

published on 05/08/2025 at 14:00, 6 months 28 days ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
Aspire Biopharma to present at Sidoti Virtual Investor Conference on May 21 and host virtual one-on-ones with investors. Company's disruptive drug delivery technology highlighted

Sidoti Virtual Investor Conference Virtual Presentation One-on-one Meetings Drug Delivery Technology Aspire Biopharma

Accesswire

Published on 12/05/2025 at 17:15, 18 minutes ago

TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 17:00, 33 minutes ago

Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once
Published on 12/05/2025 at 16:00, 1 hour 33 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 1 hour 48 minutes ago

Critical Elements announce la clôture d'un placement privé de 7,0 $ million ca par voie de prise ferme
Published on 12/05/2025 at 15:45, 1 hour 48 minutes ago

Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 17:00, 32 minutes ago

EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance
Published on 12/05/2025 at 16:25, 1 hour 7 minutes ago

4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 1 hour 23 minutes ago

Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 16:00, 1 hour 32 minutes ago

EQS-Adhoc: TIN INN Holding AG implements financing strategy
Published on 12/05/2025 at 16:00, 1 hour 32 minutes ago

EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025

Les Echos

Published on 12/05/2025 at 17:18, 15 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 15 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 2 hours 22 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 2 hours 22 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 3 hours 34 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE